DNAPrint subsidiary completes development of anemia test

By Elaine Rigoli

Tampa, Fla., Aug. 4 - KBI BioPharma, Inc. completed and validated a second analytical method for PT-401, based on SDS-PAGE, an established separation technique for in-process analysis, release and stability testing for its PT-401 anemia drug, which is being developed by its subsidiary, DNAPrint Pharmaceuticals, Inc.

"Separation of proteins plays a major role in characterizing [Good Manufacturing Practices] GMP material, which in turn is necessary to advance preclinical testing of PT-401 and to prepare a successful Investigational New Drug filing with the Food and Drug Administration. We are very pleased with the progress of the research to date and we are especially pleased with KBI BioPharma's development of this crucial step," DNAPrint chairman and chief medical officer Hector J. Gomez said in a news release.

DNAPrint, based in Sarasota, Fla., develops genomics-based products and services for biomedical and forensics purposes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.